Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Casaluce

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Expert Opinion on Emerging Drugs|May 5, 2023
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?Francesca Casaluce, Cesare Gridelli
Translational Lung Cancer Research|February 11, 2021
Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issuesFrancesca Casaluce, Cesare Gridelli
Expert Opinion on Biological Therapy|March 10, 2017
The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderlyAssunta Sgambato, Francesca Casaluce, Cesare Gridelli
Expert Review of Anticancer Therapy|December 1, 2017
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitorsAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Translational Lung Cancer Research|May 18, 2016
Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the questionCesare Gridelli, Francesca Casaluce, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|March 2, 2013
Emerging mitotic inhibitors for non-small cell carcinomaFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Journal of Thoracic Disease|June 29, 2018
Lung cancer, elderly and immune checkpoint inhibitorsFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Expert Opinion on Investigational Drugs|July 5, 2017
Selumetinib for the treatment of non-small cell lung cancerFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Cancer Treatment Reviews|August 13, 2013
ALK inhibitors in the treatment of advanced NSCLCCesare Gridelli, Solange Peters, Assunta Sgambato, et al.
Therapeutic Advances in Medical Oncology|September 2, 2015
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationPaolo Maione, Paola Claudia Sacco, Assunta Sgambato, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Expert Opinion on Emerging Drugs|May 5, 2023
Combined chemo-immunotherapy in advanced non-small cell lung cancer: feasible in the elderly?Francesca Casaluce, Cesare Gridelli
Translational Lung Cancer Research|February 11, 2021
Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issuesFrancesca Casaluce, Cesare Gridelli
Expert Opinion on Biological Therapy|March 10, 2017
The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderlyAssunta Sgambato, Francesca Casaluce, Cesare Gridelli
Expert Review of Anticancer Therapy|December 1, 2017
Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitorsAssunta Sgambato, Francesca Casaluce, Paolo Maione, et al.
Translational Lung Cancer Research|May 18, 2016
Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that's the questionCesare Gridelli, Francesca Casaluce, Assunta Sgambato, et al.
Expert Opinion on Emerging Drugs|March 2, 2013
Emerging mitotic inhibitors for non-small cell carcinomaFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Journal of Thoracic Disease|June 29, 2018
Lung cancer, elderly and immune checkpoint inhibitorsFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Expert Opinion on Investigational Drugs|July 5, 2017
Selumetinib for the treatment of non-small cell lung cancerFrancesca Casaluce, Assunta Sgambato, Paolo Maione, et al.
Cancer Treatment Reviews|August 13, 2013
ALK inhibitors in the treatment of advanced NSCLCCesare Gridelli, Solange Peters, Assunta Sgambato, et al.
Therapeutic Advances in Medical Oncology|September 2, 2015
Overcoming resistance to targeted therapies in NSCLC: current approaches and clinical applicationPaolo Maione, Paola Claudia Sacco, Assunta Sgambato, et al.
Pageof 4